#USA #Allentown #Exubrion Therapeutics #Synovetin OA #Canine Arthritis

Revolutionary Treatment for Canine Osteoarthritis

In a remarkable achievement for veterinary medicine, Exubrion Therapeutics has just announced that the 100th veterinary hospital has been licensed to offer Synovetin OA. This innovative treatment is revolutionizing the way canine osteoarthritis is managed, providing long-lasting pain relief for our furry friends. Located at the Eastern Pennsylvania Veterinary Medical Center in Allentown, PA, this milestone signifies a growing commitment within the veterinary community to adopt evidence-based therapies.

Understanding Synovetin OA

Synovetin OA is a targeted medical radiotherapy that addresses osteoarthritis (OA) in dogs. This disease affects one out of every four adult canines and up to 80% of seniors, often resulting in chronic discomfort, decreased mobility, and reduced quality of life. Traditional treatments have relied heavily on short-acting medications that primarily relieve symptoms without addressing the underlying cause.

What sets Synovetin OA apart is its unique delivery method. Administered as a single injection directly into the affected joint, the treatment utilizes tin-117m microparticles. These particles deactivate and eliminate the inflammatory cells responsible for arthritis pain and joint degeneration. The advantages of this treatment include:

• - Extended Relief: Dogs receive up to a full year of relief from just one injection.
• - Comprehensive Effectiveness: Proven efficacy for dogs at all stages of OA, from mild to severe.
• - High Safety Profile: The treatment specifically targets only the treated joint, posing minimal risk to other organs.
• - Convenience: Pet owners won't face the hassle of daily medications or frequent vet visits.

The Clinical Backing

Recent research published in Frontiers in Veterinary Science suggests that the potential of tin-117m as a disease-modifying therapy is significant. Studies demonstrate its ability to reduce inflammation and cartilage degeneration in preclinical trials, confirming the potential for long-lasting pain relief in dogs.

Dr. Berit Fischer, who leads the Synovetin OA initiative at the Allentown facility, emphasizes the treatment's innovative approach. With years of experience in veterinary anesthesia and pain management, she integrates Synovetin OA into her treatment plans, especially when dealing with OA limited to one or two joints or in cases of early developmental disorders.

"Many patients are forced to rely on NSAIDs and joint supplements, but Synovetin OA offers a fresh perspective on treating osteoarthritis," says Dr. Fischer. "My recommendation for managing cases involving OA has shifted to prioritize this groundbreaking treatment."

Looking Forward

Exubrion Therapeutics is optimistic about the future of Synovetin OA, especially with the significant number of licensed veterinarians offering this treatment. They're striving to make this therapy a standard care option for canine arthritis, ensuring that more dogs can reap the benefits of active, pain-free lives.

As the network of veterinary practices using Synovetin OA continues to grow, pet owners can look forward to improved health and wellbeing for their dogs. With Exubrion's ongoing commitment to innovation in veterinary healthcare, we can expect more success stories and advancements in the treatment landscape for canine arthritis.

For pet owners interested in finding local veterinarians who provide Synovetin OA, further information can be found at ActiveDogNow.com.

About Exubrion Therapeutics

Founded with a mission to enhance the quality of life for animals suffering from arthritis, Exubrion Therapeutics specializes in the development of pioneering treatments like Synovetin OA. By utilizing advanced radiotherapeutic strategies, the company aims to transform arthritic care for canines, prioritizing effective, safe, and long-lasting solutions. With the recent licensing milestone, Exubrion is well on its way to achieving its vision of a future where no dog suffers unnecessarily from arthritis-related pain.